Common Stock, par value $0.001 per share
- Symbol
- CODX
- Exchange
- NASDAQ
- Classification
- COMMON
Current Report · Items 5.07 · 8-K
Co-Diagnostics, Inc.
CODXNASDAQEQUITYCurrent
Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. As previously disclosed, on September 3, 2026, Co-Diagnostics, Inc. (the “Company”) held its previously announced Annual Meeting of Stockholders (the “Annual Meeting”). Because a quorum was not present or represented, the Company was unable to transact business at the Annual Meeting.…
Company context
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.
Current securities
Recent company filings
- DEF 14A filingOct 26, 2026
- PRE 14A filingOct 16, 2026
- Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity SecuritiesOct 15, 2026
- Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity SecuritiesOct 13, 2026
- Submission of Matters to a Vote of Security HoldersOct 5, 2026
Registered securities in this filing
CO-DIAGNOSTICS, INC. · 8-K · Filed 2026-10-15
Disclosure sections
Item 5.07Item 5.07 - Submission of Matters to Vote
Item
5.07. Submission of Matters to a Vote of Security Holders.
As
previously disclosed, on September 3, 2026, Co-Diagnostics, Inc. (the “Company”) held its previously announced Annual Meeting
of Stockholders (the “Annual Meeting”). Because a quorum was not present or represented, the Company was unable to transact
business at the Annual Meeting. The Annual Meeting was subsequently adjourned and reconvened on September 24, 2026 and September 30,
2026, but a quorum was not present or represented on either date. The Annual Meeting was therefore adjourned again to October 14, 2026.
On
October 14, 2026, the Company reconvened the Annual Meeting. A quorum was not present or represented, and the Company was therefore unable
to transact business at the Annual Meeting. The Company determined not to adjourn the Annual Meeting again.
The
Company currently intends to seek stockholder approval of the proposals that were to be considered at the Annual Meeting at a special
meeting of stockholders to be held on a future date. If the Company proceeds with such special meeting, the Company will announce the
date, time and location of the special meeting and provide additional information regarding the special meeting and the matters to be
considered thereat in proxy materials to be filed with the Securities and Exchange Commission and distributed to the Company’s
stockholders.